Subcutaneous Administration of Monoclonal Antibodies in Oncology
Open accessThe DOI matches its Crossref record; 25 of the 25 references it cites were found in a registry or an index.
Abstract
Treatment with monoclonal antibodies (mabs) has become an established component of oncological therapy. The monoclonal antibodies available for this purpose are mainly administered intravenously in individually adapted doses according to body weight over longer treatment times. For other chronic diseases such as, for example, diabetes mellitus, the subcutaneous administration of drugs is an established therapy option. For the subcutaneous administration of larger volumes as needed for mab solutions the extracellular matrix of the subcutaneous tissue represents a problem. The co-formulation with recombinant human hyaluronidase makes the relatively pain-free administration of larger fluid volumes and thus the subcutaneous administration of monoclonal antibodies possible, as illustrated by the development of a subcutaneous formulation of trastuzumab. This constitutes a less invasive, time-optimised and flexible form of administration for patients with HER2-positive breast cancer that, with its fixed dosing possibilities, contributes to therapeutic safety. The example of trastuzumab shows that the subcutaneous administration of monoclonal antibodies can simplify oncological long-term therapy not only for the patients but also for the medical personnel.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“intravenous (IV) administration of anticancer biologics can present multiple challenges for many patients, including long infusion and observation times, the need for repeated, invasive IV access”
From A systematic review of time and resource use costs of subcutaneous versus intravenous administration of oncology biologics in a hospital setting (2023) · cites this paper as [27]
In the citing paper
“While the i.v. route may result in higher systemic exposures, s.c. administration is an established modality for almost all disease indications given its convenience and option of self‐administration.18”
From Tutorial on monoclonal antibody pharmacokinetics and its considerations in early development (2018) · cites this paper as [18]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Slamon, D. J., Leyland-Jones, B., Shak, S., Fuchs, H., Paton, V., Bajamonde, A., Fleming, T., Eiermann, W., Wolter, J., Pegram, M., et al. (2001) · New England Journal of Medicine · doi:10.1056/nejm200103153441101 · Cited by 11,500 · cited 1×
“…" riskofsystemicinfections For the add-on administration of trastuzumab to a standard chemotherapy, randomised phase III trials have reported median progression-free intervals of from 7.1 months [17] up to 11.1 months [18], and in randomised phase II trials of up to 18.6 months [19].”
InfluentialFizazi, K., Carducci, M., Smith, M., Damião, R., Brown, J., Karsh, L., Milecki, P., Shore, N., Rader, M., Wang, H., et al. (2011) · The Lancet · doi:10.1016/s0140-6736(10)62344-6 · Cited by 1,971
Stopeck, A. T., Lipton, A., Body, J.-J., Steger, G. G., Tonkin, K., de Boer, R. H., Lichinitser, M., Fujiwara, Y., Yardley, D. A., Viniegra, M., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2010.29.7101 · Cited by 1,597
Henry, D. H., Costa, L., Goldwasser, F., Hirsh, V., Hungria, V., Prausova, J., Scagliotti, G. V., Sleeboom, H., Spencer, A., Vadhan-Raj, S., et al. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2010.31.3304 · Cited by 1,263
Smith, M. R., Saad, F., Coleman, R., Shore, N., Fizazi, K., Tombal, B., Miller, K., Sieber, P., Karsh, L., Damião, R., et al. (2012) · The Lancet · doi:10.1016/s0140-6736(11)61226-9 · Cited by 797
Pegram, M., Hsu, S., Lewis, G., Pietras, R., Beryt, M., Sliwkowski, M., Coombs, D., Baly, D., Kabbinavar, F., & Slamon, D. (1999) · Oncogene · doi:10.1038/sj.onc.1202526 · Cited by 692
Cardoso, F., Fallowfield, L., Costa, A., Castiglione, M., & Senkus, E. (2011) · Annals of Oncology · doi:10.1093/annonc/mdr372 · Cited by 596
Cardoso, F., Harbeck, N., Fallowfield, L., Kyriakides, S., & Senkus, E. (2012) · Annals of Oncology · doi:10.1093/annonc/mds232 · Cited by 485
Ismael, G., Hegg, R., Muehlbauer, S., Heinzmann, D., Lum, B., Kim, S.-B., Pienkowski, T., Lichinitser, M., Semiglazov, V., Melichar, B., et al. (2012) · The Lancet Oncology · doi:10.1016/s1470-2045(12)70329-7 · Cited by 351
Self-citationFrost, G. I. (2007) · Expert Opinion on Drug Delivery · doi:10.1517/17425247.4.4.427 · Cited by 323
Research works printed but not linked: 4
- Davies A, Merli F, Mihaljevic B et al. Pharmacokinetics, safety, and over- all response rate achieved with subcutaneous administration of ritux- imab in combination with chemotherapy were comparable with those achieved with intravenous administration in patients with follicular lymphoma in the first-line setting: stage 1 results of the phase 3 SAB- RINA study (BO22334). Blood (ASH Annual Meeting Abstracts) 2012; 120: 1629
- Haller F. Converting intravenous dosing to subcutaneous dosing with recombinant human hyaluronidase. Pharm Tech 2007; 10: 861 -864
- Watson D. Hyaluronidase. Br J Anaesth 1993; 71: 422-425
- De Cock E, Semiglazov V, Lopez-Vivanco G et al. Time savings with tras- tuzumab subcutaneous vs. intravenous administration: a time-and- motion study. Präsentiert als Poster auf der International Breast Cancer Conference St. Gallen 2013, Abstract P209, 2013
Cited by
Pharmacokinetics of monoclonal antibodies and Fc-fusion proteins
Liu, L. (2018) · Protein & Cell · doi:10.1007/s13238-017-0408-4 · Cited by 390
Tutorial on monoclonal antibody pharmacokinetics and its considerations in early development
Ovacik, M., & Lin, K. (2018) · Clinical and Translational Science · doi:10.1111/cts.12567 · Cited by 299
Schreiber, S., Ben-Horin, S., Leszczyszyn, J., Dudkowiak, R., Lahat, A., Gawdis-Wojnarska, B., Pukitis, A., Horynski, M., Farkas, K., Kierkus, J., et al. (2021) · Gastroenterology · doi:10.1053/j.gastro.2021.02.068 · Cited by 236
Trastuzumab in the Treatment of Breast Cancer
Maximiano, S., Magalhães, P., Guerreiro, M. P., & Morgado, M. (2016) · BioDrugs · doi:10.1007/s40259-016-0162-9 · Cited by 223
High-concentration protein formulations: How high is high?
Garidel, P., Kuhn, A. B., Schäfer, L. V., Karow-Zwick, A. R., & Blech, M. (2017) · European Journal of Pharmaceutics and Biopharmaceutics · doi:10.1016/j.ejpb.2017.06.029 · Cited by 187
“Jackisch and co-workers [24] showed that it is possible to co-formulate a therapeutic monoclonal antibody (trastuzumab ) with recombinant human hyaluronidase and to generate a stable formulation.”
Background
Metadata
- Authors
- Jackisch, C., Müller, V., Maintz, C., Hell, S., & Ataseven, B.
- Affiliations
- Sana Klinikum Offenbach (DE)
- University Medical Center Hamburg-Eppendorf (DE)
- Hämatologisch-Onkologische Praxis, Würselen
- Medizinisch-wissenschaftliche Beratung, Speyer
- Kliniken Essen-Mitte (DE)
- Corresponding author
- Jackisch, C.
- Venue
- Geburtshilfe und Frauenheilkunde
- Publisher
- Georg Thieme Verlag KG
- Published
- 2014-04-28
- Volume
- 74
- Issue
- 04
- Pages
- 343-349
- ISSN
- 0016-5751 (ISSN-L)
- 1438-8804
- PMC
- PMC4078128
- OpenAlex
- W2090108443
- Cited by
- 90
- References
- 25
- Citations by year
- 2026: 2 · 2025: 7 · 2024: 9 · 2023: 13 · 2022: 13 · 2021: 14 · 2020: 8 · 2019: 4 · 2018: 9 · 2017: 7 · 2016: 3 · 2015: 1
- FWCI
- 2.87
- Type
- journal article
- Language
- de
- Open access
- bronze
- doi.org
- Locations
- Geburtshilfe und Frauenheilkunde (publishedVersion)
- Europe PMC (PubMed Central) (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Amgen
- Les Laboratories Pierre Fabre
- Topics
- Life Sciences › Immunology and Microbiology › Immunology › Monoclonal and Polyclonal Antibodies Research
- Health Sciences › Medicine › Oncology › HER2/EGFR in Cancer Research
- Life Sciences › Immunology and Microbiology › Immunology › Biosimilars and Bioanalytical Methods
- Keywords
- subcutaneous administration, monoclonal antibodies, trastuzumab, recombinant human hyaluronidase, subcutaneous formulation, HER2-positive breast cancer, extracellular matrix, fixed dosing
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Subcutaneous Administration of Monoclonal Antibodies in Oncology. https://app.cochat.ai/papers/10.1055/s-0034-1368173
- The paper
- Jackisch, C., Müller, V., Maintz, C., Hell, S., & Ataseven, B. (2014). Subcutaneous Administration of Monoclonal Antibodies in Oncology. Geburtshilfe und Frauenheilkunde. https://doi.org/10.1055/s-0034-1368173
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.